Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medications routinely given to people experiencing psychosis could be worsening some of their cognitive function, including memory and concentration, according to a new analysis of existing research.

A silhouette of a man against an orange sky with his brain lit up © Shutterstock

Researchers led by Dr Valentina Mancini and Associate Professor Rob McCutcheon at the Department of Psychiatry at the University of Oxford looked at evidence from 40 studies, with findings published in the American Journal of Psychiatry.

They looked at the data from people who had been prescribed ‘anticholinergic’ medications, which block a chemical in the brain called acetycholine, involved in facilitating the transmission of signals in the brain. These include a wide range of medications including those prescribed to mitigate the side effects of antipsychotic drugs.

They found higher use of these medications correlated with poorer general cognition, verbal and visual learning, memory, attention, executive functioning (e.g. decision making) and slower processing speed.

According to the analysis, tapering off these medicines was linked to improved scores in verbal learning, memory and executive functioning.

Dr Mancini said:

Our findings highlight the negative impact of routinely used medications on cognitive function in people with psychosis. From a clinical perspective, tapering off anticholinergic medication could be beneficial for their cognition, but further research is needed to prove this without question.”

Around 80 per cent of people with psychosis have some form of cognitive impairment, leading to high rates of unemployment and the need for long-term community support.

Anticholinergic properties are found in medications used to treat the side effects of antipsychotics as well as being in some anti-depressants, epilepsy drugs and antihistamines.

Cholinergic neurotransmission is vital for healthy cognitive processing and the current research shows how medicines with anticholinergic properties negatively affect this.

Professor McCutcheon says:

We need to do everything we can to help improve the cognitive health of people with schizophrenia. Improving cognitive health maximises the chance that people can live independent, fulfilling lives. Carefully reviewing the medications patients are prescribed and minimising the use of drugs that have anticholinergic properties is one way we can help.”

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

New audit system maps how mental-health risks emerge in AI chatbot conversations

Scientists have developed a framework for stress-testing how AI chatbots respond to vulnerable users, helping researchers identify weaknesses and test ways of making mental-health interactions safer.

AI could help identify patients at risk of psychosis more quickly

AI has been shown to be effective in identifying and analysing symptoms from psychiatric interviews, which could help speed up assessments and access to care for those who need it most, according to a new study.

Clinical Trial of Ketogenic Therapy for Early Psychosis funded by Baszucki Group

The University Oxford has received £1.17m of funding from Baszucki Group to assess the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P).

New psychiatry textbook by Oxford experts published

The latest edition of the Shorter Oxford Textbook of Psychiatry has just been published by Oxford University Press.

Targeted TUNE‑UP service boosts access to clozapine for patients - new paper

A new study examining the impact of an innovative clinic has highlighted its significant impact, showing a dramatic increase in the number of patients able to start clozapine safely in the community.

New study offers breakthrough in detecting risk for psychosis and bipolar disorders

A study published recently in The Lancet Psychiatry has unveiled a new approach to identifying individuals at risk of developing psychotic disorders or bipolar disorder.